Abstract Background and Aims; To investigate the association between use of angiotensin-
converting enzyme inhibitor (ACEI)/angiotensin-receptor blocker (ARB) and outcomes of …

Aims: We sought to evaluate the association of angiotensin-converting-enzyme inhibitors
(ACEI) or AT1 blockers (ARB) therapy with clinical outcomes in patients with coronavirus …

Introduction The use of renin-angiotensin system (RAS) inhibitors, including angiotensin-
converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), was …

Aims This meta-analysis provides summary odds ratio (OR) estimates for associations
between treatment with (vs. without) renin–angiotensin system blockers and risk of severe …

Abstract Purpose of Review While the COVID-19 pandemic is constantly evolving, it remains
unclear whether the use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin …

What is known and Objective Controversy has arisen in the scientific community on whether
the use of renin‐angiotensin system (RAS) inhibitors in the context of COVID‐19 would be …

Renin–angiotensin–aldosterone system (RAAS) inhibitors, including angiotensin‐converting
enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are one of the most …

Background and rationale Some studies of hospitalized patients suggested that the risk of
death and/or severe illness due to COVID-19 is not associated with the use of angiotensin …

The possible effects of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II
receptor blockers (ARBs) on COVID-19 disease severity have generated considerable …

An association among the use of angiotensin converting enzyme (ACE) inhibitors and
angiotensin‐receptor blockers (ARBs) with the clinical outcomes of coronavirus disease …